RECOMMEND Platform Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.
Also called NCT06526533
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose supportive care
- Phase
- Phase 3
- Enrolled
- 600 participants
- Registry
-
NCT06526533
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia
- Registry status
- Recruiting
Technical summary
Registry record NCT06526533. Randomized; no masking; primary purpose supportive care. Start 2026-03-23 (actual); primary completion 2028-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- RECOMMEND Platform Trial
- Acronym
- RECOMMEND
- Condition
- Extracorporeal Membrane Oxygenation Complication
- Condition
- ARDS (Acute Respiratory Distress Syndrome)
- Condition
- Intensive Care Medicine
- Condition
- Cardiac Arrest (CA)
- Condition
- Critical Illness
- Intervention (Other)
- Liberal RBC Transfusion
- Intervention (Other)
- Restrictive RBC Transfusion
- Lead sponsor
- Australian and New Zealand Intensive Care Research Centre
- Collaborator
- Monash University
- Collaborator
- Berry Consultants
- Collaborator
- Research Path
Record details
- Record id
cardio:ct-nct06526533- Content hash
17dfd96b4e68e414c7dac2e57044b1482fcfef937180e048328af3b9b5e20268